Safety Study of CD24Fc When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)
Status:
Completed
Trial end date:
2015-01-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of single ascending
intravenous (IV) doses of CD24Fc in healthy adult participants.
Phase:
Phase 1
Details
Lead Sponsor:
OncoImmune, Inc.
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)